trending Market Intelligence /marketintelligence/en/news-insights/trending/_KtH18tJZsgbB98U9DYSxw2 content esgSubNav
In This List

Flexion Therapeutics appoints chief medical officer amid buyout rumors

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Flexion Therapeutics appoints chief medical officer amid buyout rumors

Flexion Therapeutics co-founder Neil Bodick is transitioning to the position of chief scientific officer to make room for the appointment of Yamo Deniz.

Deniz will take over Bodick's duties as the chief medical officer of the company. He joins Flexion from Sanofi Genzyme where he served as vice president and head of global medical affairs for rare diseases.

The move comes amid rumors that the companies are in talks about a potential merger, the Boston Business Journal writes. Sanofi Genzyme is the specialty care global business unit of Sanofi.

Flexion is awaiting U.S. FDA approval for its Zilretta treatment in osteoarthritis of the knee.